IAS / AIDS | Melbourne Convention and Exhibition Centre | Australia
Since Gilead is a major global force in the treatment of AIDS, the company’s presence at the International AIDS Conference in Melbourne was a given. The number of people in developing countries receiving Gilead antiretroviral therapy has increased from fewer than 30,000 in 2006 to 6.7 million in 2014. More than half of the people now treated for HIV in developing world countries receive Gilead medicines. This conference was critical to Gilead’s mission to discover, develop and deliver therapies to improve the lives of patients around the world.